ClinicalTrials.gov
ClinicalTrials.gov Menu

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00480025
Recruitment Status : Terminated (The study was terminated following assessment of the lack of efficacy of the study product by the Independent Data monitoring Committee for the study.)
First Posted : May 30, 2007
Last Update Posted : December 21, 2015
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : December 2013
  Actual Study Completion Date : September 2014
  Certification/Extension First Submitted : August 22, 2013

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 5, 2016 January 27, 2017
2 March 21, 2017 April 28, 2017
3 October 23, 2017 November 28, 2017